title: Comparison of respiratory parameters and plasma cytokine levels between treatment with Salmeterol/fluticasone and ipratropium/terbutaline/budesonide in mechanically ventilated COPD patients.
abstract: BACKGROUND
  It is unknown whether the bronchodilation and anti-inflammatory effects of inhaled salmeterol and fluticasone (SF) are better than those of traditionally inhaled ipratropium, terbutaline and budesonide (ITB) in mechanically ventilated patients with chronic obstructive pulmonary disease (COPD).
  
  
  METHODS
  Nineteen stable COPD patients with respiratory failure were randomly enrolled into two groups. Patients were treated with inhaled SF delivered by a metered-dose inhaler with a spacer or with inhaled nebulized ITB. Respiratory parameters were measured for 7 days and plasma cytokine levels were measured on days 1 and 7.
  
  
  RESULTS
  The kinetic curve of the rapid shallow index (RSI) from day 1 to day 7 was significant lower in the SF group than that in the ITB group. There were no significant differences in minute ventilation, intrinsic positive end expiratory pressure, and airway resistance between the ITB and SF groups from day 1 to day 7. There were no differences in plasma interleukin (IL)-6, IL-10, IL- 12, and transforming growth factor-beta1 levels between day 1 and day 7 in the ITB or SF group.
  
  
  CONCLUSIONS
  Patients with inhaled SF treatment had a lower RSI. The effects of bronchodilators and anti-inflammation were similar between inhaled SF and ITB in COPD patients with ventilator support.
authors.affiliation: Division of Pulmonary, Critical Care and Sleep Medicine, Chang Gung Memorial Hospital at Keelung, Chang Gung University College of Medicine, Taoyuan, Taiwan.
authors.forename: Huang-Pin
authors.initials: HP
authors.lastname: Wu
authors.forename: Yu-Chih
authors.initials: YC
authors.lastname: Liu
authors.forename: Shi-Chuan
authors.initials: SC
authors.lastname: Lin
authors.forename: Ming-Yi
authors.initials: MY
authors.lastname: Chien
authors.forename: Fang-Chun
authors.initials: FC
authors.lastname: Liao
authors.forename: Shu-Chuan
authors.initials: SC
authors.lastname: Chang
authors.forename: Wen-Bin
authors.initials: WB
authors.lastname: Shieh
mesh_terms: D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D019819:Budesonide / Q000008:administration & dosage*; D016207:Cytokines / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012129:Respiratory Function Tests; D000068299:Salmeterol Xinafoate; D013726:Terbutaline / Q000008:administration & dosage*
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D001993:Bronchodilator Agents; D016207:Cytokines; D019819:Budesonide; D000068299:Salmeterol Xinafoate; D009241:Ipratropium; D013726:Terbutaline; D000420:Albuterol